Suman Rao

13.3k total citations · 3 hit papers
21 papers, 9.3k citations indexed

About

Suman Rao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Suman Rao has authored 21 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Suman Rao's work include Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Suman Rao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Suman Rao collaborates with scholars based in United States, Spain and Hungary. Suman Rao's co-authors include Tibor Csőszi, Delvys Rodríguez‐Abreu, Katsuyuki Hotta, Sinéad Cuffe, Ali Tafreshi, Rina Hui, Nir Peled, Julie R. Brahmer, Maya Gottfried and Andrew Robinson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Suman Rao

21 papers receiving 9.2k citations

Hit Papers

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–... 2016 2026 2019 2022 2016 2019 2021 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
    2016 7.1k citations Martin Reck, Delvys Rodríguez‐Abreu et al. New England Journal of Medicine profile →
  2. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
    2019 1.1k citations Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology profile →
  3. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
    2021 616 citations Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suman Rao United States 10 7.9k 5.4k 1.8k 1.2k 895 21 9.3k
Andrea Fülöp Hungary 9 7.9k 1.0× 5.3k 1.0× 1.8k 1.0× 1.2k 1.0× 898 1.0× 14 9.2k
Melanie A. Leiby United States 6 6.1k 0.8× 3.9k 0.7× 1.5k 0.8× 930 0.8× 795 0.9× 7 7.2k
Hossein Borghaei United States 43 7.2k 0.9× 4.6k 0.9× 1.9k 1.0× 1.0k 0.9× 1.4k 1.5× 258 9.0k
Tibor Csőszi United States 22 9.1k 1.1× 5.8k 1.1× 1.9k 1.1× 1.3k 1.1× 1.3k 1.4× 82 10.7k
Reshma Rangwala United States 18 7.0k 0.9× 4.4k 0.8× 1.8k 1.0× 1.2k 1.0× 1.4k 1.6× 41 9.2k
Yue Shentu United States 15 10.7k 1.3× 7.0k 1.3× 2.5k 1.4× 1.5k 1.3× 1.3k 1.5× 34 12.6k
Mary J. Fidler United States 22 5.2k 0.7× 3.7k 0.7× 1.1k 0.6× 748 0.6× 803 0.9× 115 6.4k
Naoyuki Nogami Japan 30 5.9k 0.7× 5.4k 1.0× 757 0.4× 969 0.8× 1.4k 1.6× 149 7.4k
Jamie E. Chaft United States 43 7.0k 0.9× 6.4k 1.2× 1.0k 0.5× 1.5k 1.3× 1.9k 2.1× 175 10.2k
Daniil Stroyakovskiy Russia 28 7.2k 0.9× 3.7k 0.7× 1.4k 0.8× 1.2k 1.0× 2.6k 2.9× 114 8.7k

Countries citing papers authored by Suman Rao

Since Specialization
Citations

This map shows the geographic impact of Suman Rao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suman Rao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suman Rao more than expected).

Fields of papers citing papers by Suman Rao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suman Rao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suman Rao. The network helps show where Suman Rao may publish in the future.

Co-authorship network of co-authors of Suman Rao

This figure shows the co-authorship network connecting the top 25 collaborators of Suman Rao. A scholar is included among the top collaborators of Suman Rao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suman Rao. Suman Rao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pohlmann, Paula R., Deena Graham, Yvonne Ottaviano, et al.. (2022). HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast Cancer Research and Treatment. 196(3). 571–581. 4 indexed citations
3.
Geng, Xue, Suman Rao, Kevin Y. Chen, et al.. (2022). Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy. Clinical Lung Cancer. 23(5). 438–445. 4 indexed citations
4.
5.
Reck, Martin, Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2021). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology. 39(21). 2339–2349. 616 indexed citations breakdown →
6.
Ahn, Jaeil, et al.. (2021). Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer. The Oncologist. 26(8). 694–700. 6 indexed citations
7.
Zhu, Viola W., Christine M. Bestvina, Gilberto Lopes, et al.. (2021). Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.. Journal of Clinical Oncology. 39(15_suppl). TPS9136–TPS9136. 2 indexed citations
8.
Bravo, Gabriela, Anas Belouali, Paul Sackstein, et al.. (2021). P21.07 Immune-Related Adverse Events with Durvalumab Consolidation in a Real-World Cohort of Patients with Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 16(3). S366–S366. 1 indexed citations
9.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Rina Hui, et al.. (2020). LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%. Annals of Oncology. 31. S1181–S1182. 61 indexed citations
10.
Reck, Martin, Delvys Rodríguez‐Abreu, Rina Hui, et al.. (2019). OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S243–S243. 29 indexed citations
11.
Davidson, Martin, Sonia Mansukhani, Naureen Starling, et al.. (2019). Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in. Annals of Oncology. 30. v254–v254. 1 indexed citations
12.
Reck, Martin, Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2019). Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology. 37(7). 537–546. 1121 indexed citations breakdown →
13.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2018). PS3 KEYNOTE-024 Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC with PD-L1 Tumor Proportion Score ≥50%. Journal of Thoracic Oncology. 13(9). S153–S153. 2 indexed citations
14.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%. Journal of Thoracic Oncology. 12(11). S1793–S1794. 57 indexed citations
15.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. Journal of Thoracic Oncology. 12(1). S8–S9. 10 indexed citations
16.
Garon, Edward B., Martin Reck, Delvys Rodríguez‐Abreu, et al.. (2017). P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1290–S1291. 1 indexed citations
17.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. The Lancet Oncology. 18(12). 1600–1609. 255 indexed citations
18.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.. Journal of Clinical Oncology. 35(15_suppl). 9000–9000. 42 indexed citations
19.
Reck, Martin, Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2016). KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. Annals of Oncology. 27. vi578–vi578. 12 indexed citations
20.
Reck, Martin, Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 375(19). 1823–1833. 7054 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Fülöp Breakdown of academic impact, for papers by Melanie A. Leiby Breakdown of academic impact, for papers by Hossein Borghaei Breakdown of academic impact, for papers by Tibor Csőszi Breakdown of academic impact, for papers by Reshma Rangwala Breakdown of academic impact, for papers by Yue Shentu Breakdown of academic impact, for papers by Mary J. Fidler Breakdown of academic impact, for papers by Naoyuki Nogami Breakdown of academic impact, for papers by Jamie E. Chaft Breakdown of academic impact, for papers by Daniil Stroyakovskiy
Rankless by CCL
2026